瓦雷尼克林通过减少吸烟对戒烟的影响:一项随机临床试验
Jon O Ebbert1, John R Hughes2, Robert J West3
1Mayo Clinic, Rochester, Minnesota.
JAMA
|February 18, 2015
概括
瓦伦尼克林显著增加了吸烟者戒烟率,旨在在戒烟之前减少吸烟. 这种药物为那些不准备立即戒烟的人提供了一个可行的选择,在治疗结束和一年后改善戒烟率.
科学领域:
- 临床医学 临床医学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 许多吸烟者还没有准备好立即戒烟,但可能愿意减少吸烟,以未来的戒烟目标.
- 减少吸烟是迈向完全戒烟的潜在中间步骤.
研究的目的:
- 通过吸烟减少策略来评估瓦雷尼克林在提高吸烟戒断率方面的疗效和安全性.
- 为那些不愿意或无法突然戒烟的吸烟者提供替代治疗.
主要方法:
- 一个随机的,双盲的,安慰剂控制的,涉及1510名参与者的跨国试验.
- 参与者接受了24周的瓦雷尼克林或安慰剂,旨在显著减少吸烟,并在12周内尝试戒烟.
- 主要终点:第一氧化碳证实了15-24周的戒断;次要:21-24周和21-52周的戒断.
主要成果:
- 与安慰剂相比,瓦伦尼克林在15-24周 (32.1%对6.9%) 和21-52周 (27.0%对9.9%) 的连续戒断率显著增加.
- 对于二次结局时期的瓦雷尼克林,也观察到更高的戒断率.
- 在瓦伦尼克林组 (3.7%) 与安慰剂组 (2.2%) 中,严重不良事件略高,尽管在统计学上不显著 (P=.07).
结论:
- 在戒烟前试图减少吸烟的吸烟者中,24周使用瓦伦尼克林有效地增加了戒烟率.
- 这些发现支持瓦雷尼克林作为一种有价值的治疗选择,用于不符合突然戒烟标准的吸烟者.
- 这种方法解决了目前关于戒烟支持的临床指南中的差距.
更多相关视频
06:12Using Nicotine in a Silica-Exposed Mouse Model to Promote Lung Epithelial-Mesenchymal Transition
Published on: March 3, 2023
1.4K
09:30A Microcontroller Operated Device for the Generation of Liquid Extracts from Conventional Cigarette Smoke and Electronic Cigarette Aerosol
Published on: January 18, 2018
9.1K
相关概念视频
Drugs Acting on Autonomic Ganglia: Stimulants
2.3K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
2.3K
Stimulants
1.4K
Stimulants are substances that enhance neural activity and elevate dopamine levels in the brain, leading to their highly addictive nature. These drugs include cocaine, amphetamines, MDMA, caffeine, and nicotine, each with distinct mechanisms of action and varied health implications.
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
1.4K
CNS Depressants: Alcohol and Nicotine
1.7K
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
1.7K
Antidepressant Drugs: MAOIs and Other Agents
1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
1.1K
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
1.1K
COPD: Management Using Bronchodilators and Corticosteroids
1.2K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.2K
